Cancer Immune Surgery

The world's first new paradigm of "Immune Surgery and Universal Treatment for various solid tumors"

Mechanism of Action

UMPIC: Ultro-Minimum Incision Personalized Intratumoral Chemoimmunotherapy

The remarkable efficacy of sustained-release library therapy is rooted in its profound understanding and clinical realization of the Abscopal Effect.

By initiating a series of sequentially occurring biological events through intratumoral injection of its core compound formulation, UMPIC induces systemic immunity from local killing.

  • Step 1: Induce immunogenic cell death and release tumor antigens
  • Step 2: Enhance the cross-presentation of antigens
  • Step 3: Promote chemotaxis and tumor infiltration of effector T cells
  • Step 4: Cytotoxic T lymphocyte-mediated tumor cell killing
  • Step 5: Form long-lasting immune memory
  • Step 6: Modulate the immunosuppressive microenvironment
Mechanism of Action
Guidelines
Mechanism

Self-Nanotechnology: In Situ Carrier Formation

A wholly original innovation: drug carriers form directly inside the tumor, not in a test tube.

The UMIPIC formulation comprises two chemotherapeutic agents that function as immunogenic haptens, combined with a sustained-release agent. Upon intratumoral injection, these components spontaneously self-assemble into fine nanoparticles — distributed uniformly throughout the tumor tissue in an interconnected network for prolonged, localized drug release.

This in situ formation surpasses the capabilities of conventional test-tube nanoparticle synthesis, and is designated self-nanotechnology.

7–20
days of sustained local drug release
~60nm
average self-nano particle size
Self-nanotechnology formation Sustained drug release kinetics

Compound Drug Combination Design

Base Layer

Anti-cancer drugs (IOS-1)

Direct intratumoral killing of tumor cells, releasing a large amount of tumor-associated antigens from coagulated tumor tissue to provide "attack targets" for the immune system.

Core Layer

Sustained-release agent

Acts as a "reservoir", maintaining high concentrations locally for 7-20 days, avoiding rapid metabolism and greatly reducing systemic toxic side effects.

Guide Layer

Immune adjuvant

Functions as an "amplifier" and "navigator", modifying released tumor antigens to be recognized by dendritic cells, enhancing the body's specific immune response.

Hydralazine molecular structure

Hydralazine

Cytarabine (Ara-C) molecular structure

Cytarabine (Ara-C)

DNP hapten molecular structure

2,4-Dinitrophenol (DNP hapten)

Neoantigen Discovery

Neoantigen Discovery After UMIPIC

UMIPIC is not merely a cytotoxic platform — it is an in vivo neoantigen factory.

Beyond direct cytotoxicity, UMIPIC induces immunogenic cell death (ICD), releasing DAMPs that convert dying tumor cells into endogenous "vaccines." The post-UMIPIC tumor becomes an enriched source of tumor-specific neoantigens, creating an ideal window for discovery.

1

Post-UMIPIC biopsy at 72–96 hours (peak ICD window)

2

Whole-exome & RNA sequencing of tumor and germline DNA

3

In silico HLA binding prediction of candidate peptides

4

Mass spectrometry validation of naturally presented neoantigens

5

Functional T-cell reactivity assays (ELISpot, ICS, cytotoxicity)

Applications: personalized cancer vaccines, adoptive T-cell therapy, MRD biomarkers, and combination with PD-1/PD-L1 checkpoint inhibitors.

Cancer Interception via the Abscopal Effect

First described by Dr. R.H. Mole in 1953 (The British Journal of Radiology), the abscopal effect has been re-engineered by UMIPIC from a radiobiological curiosity into a pharmacologically-induced, multi-tiered interception strategy.

Cancer interception mechanism
Level Target Effect
1 Macroscopic metastases Primed CD8⁺ CTLs travel via the bloodstream to eliminate established distant metastatic deposits.
2 Circulating tumor cells (CTCs) Sustained memory T-cell surveillance intercepts CTCs before they can colonize distant organs.
3 Pre-metastatic niches & micrometastases Activated immunity eradicates subclinical disease foci below imaging detection — true cancer interception.

Clinical evidence: circulating tumor cells suppressed in 80% of monitored patients post-UMIPIC.

The Next Frontier: Immuno-Neuro-Oncology (INO)

The UMIPIC-induced abscopal effect is not only a peripheral immune phenomenon — it is also subject to central nervous system regulation.

In Situ Ignition

Intratumoral UMIPIC injection induces local immunogenic cell death and sustained antigen release — the "local fire."

Systemic Propagation

Dendritic cells cross-present released neoantigens, activating a polyclonal T-cell response — the "classical abscopal fire."

Neuro-Immune Amplification

The brain senses inflammatory signals and amplifies the immune response via hormonal and neurotransmitter pathways — the "central ignition controller."

This convergence of oncology, immunology, and neuroscience represents a new frontier in achieving durable remission and functional cures.